Regeneron Presents New Phase 3 Analyses Showing a Single Dose of REGEN-COV (casirivimab and imdevimab) Provides Long-term Protection Against COVID-19

Regeneron Presents New Phase 3 Analyses Showing a Single Dose of REGEN-COV (casirivimab and imdevimab) Provides Long-term Protection Against COVID-19

Regeneron announced additional positive results from a Phase 3 trial which assessed use of a single dose of investigational REGEN-COV (1,200 mg administered via 4 subcutaneous injections) to prevent COVID-19 in uninfected individuals. REGEN-COV was able to reduce the risk for SARS-CoV-2 infection by 81.6% during the second to eighth month follow-up period and maintained the 81.4% risk reduction rate seen in in the first month. Initial data were published in The New England Journal of Medicine in September. 

REGEN-COV is composed of two monoclonal antibodies that block the infectivity of SARS-CoV-2 using the company's VelociSuite and VelocImmune technologies. 

The double-blind, placebo-controlled trial enrolled people who lived in the same household as an individual who was diagnosed with SARS-CoV-2 within the prior 4 days. During the trial, participants were tested weekly for SARS-CoV-2 during the initial month (4 weeks), as part of the primary analyses. Following this, from months 2-8 (week 5 to week 32), participants were to be tested if they developed any COVID-19 symptoms.

Per the previously published data, the trial met its primary endpoint, reducing the risk of...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee